UPLC-MS/MS to Support Preclinical and Clinical Antiretroviral Pharmacology Studie

UPLC-MS/MS 支持临床前和临床抗逆转录病毒药理学研究

• 批准号: 8051351
• 负责人: Angela D Kashuba
• 金额: $ 38.76万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-01 至 2012-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8051351
• 关键词: AIDS prevention; AIDS/HIV problem; Acquired Immunodeficiency Syndrome; Analytical Chemistry; Anti-Retroviral Agents; Area; Basic Science; Businesses; Capital; Clinical; Clinical Pharmacology; Clinical Sciences; Economics; Ensure; Extramural Activities; Family health status; Fees; Foundations; Funding; Genital system; Growth; Housing; Institutes; Institution; International; Maintenance; North Carolina; Occupations; Pharmacology; Pharmacy Schools; Recovery; Research; Research Personnel; System; Technology; Time; United States National Institutes of Health; Universities; Workload; cost; innovation; instrument; instrumentation; mouse model; peer; pre-clinical; success

DESCRIPTION (provided by applicant): The purpose of this proposal is to provide a second dedicated UPLC-MS/MS instrument to the established Clinical Pharmacology and Analytical Chemistry Core (CPACC) of the University of North Carolina at Chapel Hill (UNC-CH) Center for AIDS Research (CFAR). The CPACC has an 11-year record of providing a state-of- the-art centralized CLIA-certified unit to sustain the pharmacology and analytical studies of HIV/AIDS related clinical and basic science research at UNC-CH, the collaborating institutions of Family Health International and Research Triangle Institute, and to extramural CFARs. The success of the CPACC is best exemplified by the outstanding score it received from peer reviewers during the UNC CFAR's five-year renewal in 2005 for support of domestic and international investigators through analytical innovation. Since that time, the CPACC has continued to grow, and now assists more than 50 users per year. The CPACC has demonstrated success on the Agilent 6410A Triple Quadrupole LC-MS/MS System purchased in 2007. This instrument is being used full-time for network HIV prevention studies. Because of this workload, and due to lack of additional instrumentation, other key projects requiring MS/MS technology (eg humanized mouse model pharmacology for HIV prevention and cure, cellular pharmacology of antiretrovirals in the genital tract) are either on hold, or are being turned down. The addition of a second UPLC-MS/MS instrument will support NIH-funded CFAR investigators to ensure that their projects can be completed quickly and efficiently, will create job opportunities for those in the Research Triangle Area, will provide capital to local businesses, and build a foundation for longer-term economic growth within the UNC-CH system. A cost recovery fee plan guarantees the financial viability for the instrument. Dr. Angela DM Kashuba (Director of the CPACC) serves as PI of the proposal and will be responsible for all aspects of instrument maintenance and efficient usage in generating new bioanalytical innovations. The instrument will be housed in the School of Pharmacy with the other analytical instruments of the CPACC.

描述（由申请人提供）：本提案旨在为北卡罗来纳州大学查佩尔山（UNC-CH）艾滋病研究中心（CFAR）已建立的临床药理学和分析化学核心（CPACC）提供第二台专用UPLC-MS/MS仪器。该CPACC有11年的记录，提供了一个国家的最先进的中央CLIA认证的单位，以维持药理学和艾滋病毒/艾滋病相关的临床和基础科学研究在UNC-CH，家庭健康国际和研究三角研究所的合作机构，以及校外CFAR的分析研究。2005年，该委员会为支持国内和国际调查人员进行分析创新而进行了五年的更新，在此期间，该委员会获得了同行评审员的高分，这是该委员会成功的最好例证。自那时以来，CPACC不断发展壮大，现在每年为50多个用户提供帮助。CPACC在2007年购买的Agilent 6410 A三重四极杆LC-MS/MS系统上取得了成功。这一工具目前正被全时用于网络艾滋病毒预防研究。由于这一工作量，并由于缺乏额外的仪器，其他关键项目需要MS/MS技术（如人源化小鼠模型药理学艾滋病毒的预防和治疗，生殖道抗逆转录病毒药物的细胞药理学）要么被搁置，或被拒绝。增加第二台UPLC-MS/MS仪器将支持NIH资助的CFAR调查人员，以确保他们的项目能够快速有效地完成，为研究三角区的人员创造就业机会，为当地企业提供资金，并为UNC-CH系统内的长期经济增长奠定基础。成本回收收费计划保证了该工具的财务可行性。Angela DM Kashuba博士（CPACC主任）担任该提案的PI，并将负责仪器维护和有效使用的各个方面，以产生新的生物分析创新。该仪器将与CPACC的其他分析仪器一起存放在药学院。